A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy

The ability to identify robust genomic signatures that predict response to immune checkpoint blockade is restricted by limited sample sizes and ungeneralizable performance across cohorts. To address these challenges, we established Cancer-Immu (http://bioinfo.vanderbilt.edu/database/Cancer-Immu/), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jing, Zhao, Shilin, Wang, Jing, Sheng, Quanhu, Liu, Qi, Shyr, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Resource Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189237/
https://www.ncbi.nlm.nih.gov/pubmed/34903605
http://dx.doi.org/10.1158/0008-5472.CAN-21-2335
_version_ 1784725541130076160
author Yang, Jing
Zhao, Shilin
Wang, Jing
Sheng, Quanhu
Liu, Qi
Shyr, Yu
author_facet Yang, Jing
Zhao, Shilin
Wang, Jing
Sheng, Quanhu
Liu, Qi
Shyr, Yu
author_sort Yang, Jing
collection PubMed
description The ability to identify robust genomic signatures that predict response to immune checkpoint blockade is restricted by limited sample sizes and ungeneralizable performance across cohorts. To address these challenges, we established Cancer-Immu (http://bioinfo.vanderbilt.edu/database/Cancer-Immu/), a comprehensive platform that integrates large-scale multidimensional omics data, including genetic, bulk, and single-cell transcriptomic, proteomic, and dynamic genomic profiles, with clinical phenotypes to explore consistent and rare immunogenomic connections. Currently Cancer-Immu has incorporated data for 3,652 samples for 16 cancer types. It provides easy access to immunogenomic data and empowers researchers to translate omics datasets into biological insights and clinical applications. SIGNIFICANCE: Cancer-Immu is a comprehensive functional portal for unraveling immune-genomic connections to improve immune checkpoint blockade–based cancer immunotherapy.
format Online
Article
Text
id pubmed-9189237
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-91892372023-01-05 A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy Yang, Jing Zhao, Shilin Wang, Jing Sheng, Quanhu Liu, Qi Shyr, Yu Cancer Res Resource Report The ability to identify robust genomic signatures that predict response to immune checkpoint blockade is restricted by limited sample sizes and ungeneralizable performance across cohorts. To address these challenges, we established Cancer-Immu (http://bioinfo.vanderbilt.edu/database/Cancer-Immu/), a comprehensive platform that integrates large-scale multidimensional omics data, including genetic, bulk, and single-cell transcriptomic, proteomic, and dynamic genomic profiles, with clinical phenotypes to explore consistent and rare immunogenomic connections. Currently Cancer-Immu has incorporated data for 3,652 samples for 16 cancer types. It provides easy access to immunogenomic data and empowers researchers to translate omics datasets into biological insights and clinical applications. SIGNIFICANCE: Cancer-Immu is a comprehensive functional portal for unraveling immune-genomic connections to improve immune checkpoint blockade–based cancer immunotherapy. American Association for Cancer Research 2022-02-15 2021-12-13 /pmc/articles/PMC9189237/ /pubmed/34903605 http://dx.doi.org/10.1158/0008-5472.CAN-21-2335 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Resource Report
Yang, Jing
Zhao, Shilin
Wang, Jing
Sheng, Quanhu
Liu, Qi
Shyr, Yu
A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
title A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
title_full A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
title_fullStr A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
title_full_unstemmed A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
title_short A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
title_sort pan-cancer immunogenomic atlas for immune checkpoint blockade immunotherapy
topic Resource Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189237/
https://www.ncbi.nlm.nih.gov/pubmed/34903605
http://dx.doi.org/10.1158/0008-5472.CAN-21-2335
work_keys_str_mv AT yangjing apancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT zhaoshilin apancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT wangjing apancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT shengquanhu apancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT liuqi apancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT shyryu apancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT yangjing pancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT zhaoshilin pancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT wangjing pancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT shengquanhu pancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT liuqi pancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy
AT shyryu pancancerimmunogenomicatlasforimmunecheckpointblockadeimmunotherapy

Ejemplares similares